EGFRミュート化された局所進行または転移性非小細胞肺癌の患者における第一選択治療としてのオシメルチニブとオシメルチニブとの組み合わせのBL-B01D1の研究
EGFRが局所的に進行したまたは転移性非小細胞肺癌を患っている患者の第一選択治療としてのオシメルチニブとオシメルチニブとの組み合わせにおけるBL-B01D1の第III相ランダム化研究
This trial is a registered phase III, randomized, open-label, multicenter study to evaluate the efficacy and safety of BL-B01D1 in combination with osimertinib versus osimertinib as first-Line treatment in patients with EGFR-mutated locally advanced or metastatic Non-small Cell Lung Cancer.
調査の概要
研究の種類
入学 (実際)
段階
- フェーズ 3
連絡先と場所
研究場所
-
-
Shanghai Municipality
-
Shanghai、Shanghai Municipality、中国
- Shanghai East Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Sign the informed consent form voluntarily and follow the protocol requirements;
- Age ≥18 years old;
- Expected survival time ≥3 months;
- Patients with unresectable or radical radiotherapy for locally advanced non-small cell lung cancer;
- Documentation of EGFR sensitive mutations detected from tumor tissue or blood samples;
- Consent to provide archived tumor tissue samples or fresh tissue samples of primary or metastatic lesions at or after diagnosis for testing, including EGFR mutation type;
- At least one measurable lesion meeting the RECIST v1.1 definition was required;
- ECOG 0 or 1;
- The toxicity of previous antineoplastic therapy has returned to ≤ grade 1 as defined by NCI-CTCAE v5.0;
- No severe cardiac dysfunction, left ventricular ejection fraction ≥50%;
- The organ function level must meet the requirements on the premise that blood transfusion and colony-stimulating factor are not allowed within 14 days before the screening period;
- Urinary protein ≤2+ or < 1000mg/24h;
- For premenopausal women of childbearing potential, a pregnancy test must be performed within 7 days before the initiation of treatment, serum pregnancy must be negative, and the patient must not be lactating; All enrolled patients (male or female) were advised to use adequate barrier contraception throughout the treatment cycle and for 6 months after the end of treatment.
Exclusion Criteria:
- Previous histologic or cytological evidence of small cell or mixed small/non-small cell components;
- Patients with previous systemic therapy;
- Patients had received EGFR-TKI therapy;
- Studies received radical radiotherapy, major surgery, and large area radiotherapy within 4 weeks before randomization;
- History of severe heart disease and cerebrovascular disease;
- Unstable thrombotic events requiring therapeutic intervention within 6 months before screening; Infusion-related thrombosis was excluded;
- QT prolongation, complete left bundle branch block, III degree atrioventricular block, frequent and uncontrollable arrhythmia;
- Were diagnosed with active malignancy within 3 years before randomization;
- Hypertension poorly controlled by two antihypertensive drugs (systolic blood pressure > 150 mmHg or diastolic blood pressure > 100 mmHg);
- Patients with poor glycemic control;
- A history of ILD requiring steroid therapy, or current ILD or grade ≥2 radiation pneumonitis, or a suspicion of such disease;
- Complicated with pulmonary diseases leading to clinically severe respiratory function impairment;
- Patients with active central nervous system metastasis;
- Had a severe infection within 4 weeks before randomization;
- Patients with massive or symptomatic effusions or poorly controlled effusions;
- Imaging examination showed that the tumor had invaded or enveloped the large blood vessels in the abdomen, chest, neck, and pharynx;
- Serious unhealed wound, ulcer, or fracture within 4 weeks before signing the informed consent;
- Subjects with clinically significant bleeding or obvious bleeding tendency within 4 weeks before signing the informed consent;
- Patients with a history of inflammatory bowel disease, extensive bowel resection, immune enteritis, intestinal obstruction or chronic diarrhea;
- Patients with a history of allergy to recombinant humanized antibodies or to any of the excipients of BL-B01D1;
- Had autologous or allogeneic stem cell transplantation history;
- Human immunodeficiency virus antibody positive, active hepatitis B virus infection or hepatitis C virus infection;
- A history of severe neurological or psychiatric illness;
- Received other unmarketed investigational drugs or treatments within 4 weeks before randomization;
- Subjects scheduled for vaccination or who received live vaccine within 28 days before study randomization;
- Other circumstances in which the investigator considered it inappropriate to participate in the trial because of complications or other circumstances.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:BL-B01D1 in Combination with Osimertinib
Participants receive BL-B01D1 in Combination with Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Administration by intravenous infusion for a cycle of 3 weeks.
他の名前:
Oral administration, 80mg daily for a cycle of 3 weeks. |
|
アクティブコンパレータ:Osimertinib
Participants receive Osimertinib for the first cycle (3 weeks). Participants with clinical benefit could receive additional treatment for more cycles. The administration will be terminated because of disease progression or intolerable toxicity occurring or other reasons. |
Oral administration, 80mg daily for a cycle of 3 weeks. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Progression-free survival (PFS)
時間枠:Up to approximately 36 months
|
Progression-free survival (PFS) as assessed by BIRC is defined as the time between the date subjects are randomized and the first observation of disease progression (based on BICR's image-based assessment) or death. |
Up to approximately 36 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall survival (OS)
時間枠:Up to approximately 36 months
|
Overall survival (OS) is defined as the time between the subject's randomization date and subject's death. |
Up to approximately 36 months
|
|
Objective Response Rate (ORR)
時間枠:Up to approximately 36 months
|
Objective response rate (ORR) is defined as the number of CR and PR in the treatment and control groups divided by the number of that group in the full analysis set (FAS). |
Up to approximately 36 months
|
|
Disease Control Rate (DCR)
時間枠:Up to approximately 36 months
|
Disease Control Rate (DCR) : Percentage of all randomized subjects who rated the best overall response (BOR) as complete response (CR), partial response (PR), and disease stabilization (SD) according to RECIST 1.1 criteria. |
Up to approximately 36 months
|
|
Duration of Response (DOR)
時間枠:Up to approximately 36 months
|
Duration of Response (DOR) : defined as the period from the date when tumor response is first recorded to the date when objective tumor progression is first recorded or the date of death. |
Up to approximately 36 months
|
|
Treatment Emergent Adverse Event (TEAE)
時間枠:Up to approximately 36 months
|
TEAE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally emerging, or any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a pre-existing condition during the treatment of BL-B01D1. The type, frequency and severity of TEAE will be evaluated during the treatment of BL-B01D1. |
Up to approximately 36 months
|
|
Anti-drug antibody (ADA)
時間枠:Up to approximately 36 months
|
Frequency of anti-BL-B01D1 antibody (ADA) will be investigated. |
Up to approximately 36 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。